Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31362630 | 0.93 | OPRM1 (0.65) | F2OPRM1OPRD1SLC6A2 | |
| SCHEMBL30497929 | 0.92 | OPRM1 (0.64) | F2OPRM1OPRD1SLC6A2NMUR2 | |
| SCHEMBL30423827 | 0.92 | NMUR2 (0.57) | F2OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL29973454 | 0.91 | NMUR2 (0.57) | F2OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL29591831 | 0.90 | SLC6A2 (0.62) | F2OPRM1OPRD1SLC6A2 | |
| SCHEMBL31679327 | 0.89 | F2 (0.58) | F2OPRM1OPRD1SLC6A2NMUR2 | |
| SCHEMBL31362752 | 0.89 | OPRD1 (0.62) | OPRM1OPRD1SLC6A2NMUR2NMUR1 | |
| SCHEMBL31473044 | 0.89 | NMUR2 (0.58) | OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL30424056 | 0.89 | SLC6A2 (0.53) | OPRM1OPRD1SLC6A2NMUR2NMUR1 | |
| SCHEMBL31679387 | 0.88 | OPRM1 (0.66) | F2OPRM1OPRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMALN CORP (US) | 2026-01-15 | — | — | US | claimed |
| US-20230248800-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMAIN CORPORATION | 2023-08-10 | — | — | US | claimed |
| EP-4182021-A2 | V1A RECEPTOR PARTIAL AGONIST AND METHOD OF USE | Pharmain Corporation (US) | 2023-05-24 | — | — | EP | claimed |
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMALN CORP (US) | 2026-01-15 | — | — | US | disclosed |
| US-12410211-B2 | V1A receptor partial agonist and method of use | PHARMAIN CORPORATION (US) | 2025-09-09 | — | — | US | disclosed |
| US-20230248800-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMAIN CORPORATION | 2023-08-10 | — | — | US | disclosed |
| EP-4182021-A2 | V1A RECEPTOR PARTIAL AGONIST AND METHOD OF USE | Pharmain Corporation (US) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | AVPR1A, AVPR1B, AVPR2 | F2 65/4885OPRM1 98/4885OPRD1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.